| Literature DB >> 34202849 |
Natalia Martinez-Acuña1,2, Diana Minerva Avalos-Nolazco1, Diana Raquel Rodriguez-Rodriguez1, Cynthia Gabriela Martinez-Liu1,2, Kame Alberto Galan-Huerta1,2, Gerardo Raymundo Padilla-Rivas1, Javier Ramos-Jimenez2,3, Sergio Ayala-de-la-Cruz4, Eduardo Cienfuegos-Pecina4, Erik Alejandro Diaz-Chuc4, Rogelio Cazares-Tamez4, Amador Flores-Arechiga4, Fernando Perez-Chavez4, Daniel Arellanos-Soto1,2, Sonia Amelia Lozano-Sepulveda1,2, Elvira Garza-Gonzalez1, Consuelo Treviño-Garza5,6, Roberto Montes-de-Oca-Luna6,7, Aurora Beatriz Lee-Gonzalez6,8, Manuel Enrique de-la-O-Cavazos5,6, Ana Maria Rivas-Estilla1,2.
Abstract
The progression and distribution of the SARS-CoV-2 pandemic are continuously changing over time and can be traced by blood donors' serological survey. Here, we investigated the seroprevalence of anti-SARS-CoV-2 antibodies in blood donors in Nuevo Leon, Mexico during 2020 as a strategy for the rapid evaluation of the spread of SARS-CoV-2 and asymptomatic case detection. We collected residual plasma samples from blood donors who attended two regional donation centers from January to December of 2020 to identify changes in anti-SARS-CoV-2 IgG prevalence. Plasma samples were analyzed on the Abbott Architect instrument using the commercial Abbott SARS-CoV-2 IgG chemiluminescent assay. We found a total of 99 reactive samples from 2068 analyzed plasma samples, resulting in a raw prevalence of 4.87%. Donors aged 18-49 years were more likely to be seropositive compared to those aged >50 years (p < 0.001). Weekly seroprevalence increased from 1.8% during the early pandemic stage to 27.59% by the end of the year. Prevalence was 1.46-fold higher in females compared to males. Case geographical mapping showed that Monterrey city recorded the majority of SARS-CoV-2 cases. These results show that there is a growing trend of seroprevalence over time associated with asymptomatic infection that is unnoticed under the current epidemiological surveillance protocols.Entities:
Keywords: COVID-19; Mexico; anti-SARS-CoV-2 IgG; blood donors; seroprevalence
Mesh:
Substances:
Year: 2021 PMID: 34202849 DOI: 10.3390/v13071225
Source DB: PubMed Journal: Viruses ISSN: 1999-4915 Impact factor: 5.048